Sight Sciences Crescita futura
Criteri Future verificati 0/6
Sight Sciences prevede che gli utili e i ricavi cresceranno rispettivamente di 5.8% e 11% all'anno. Si prevede che l'EPS crescerà di 14.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -24.8% in 3 anni.
Informazioni chiave
5.8%
Tasso di crescita degli utili
14.54%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 17.3% |
| Tasso di crescita dei ricavi | 11.0% |
| Rendimento futuro del capitale proprio | -24.76% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 13 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Aug 18
SGHT: Medtech Procedure Trends And Glaucoma Platform Execution Will Guide Measured Repricing
Analysts have raised their price target on Sight Sciences to $8 from $6, citing more constructive views on medical technology procedure volumes and what they view as more reasonable estimates for 2026 and 2027. Analyst Commentary Recent research on Sight Sciences points to a mixed backdrop, with several firms lifting price targets while still highlighting risks around procedure trends, growth expectations and valuation.
Aggiornamento narrativa • Aug 04
SGHT: Strong Eyecare Demand And Dry Eye Coverage Will Support Upside
The fair value estimate for Sight Sciences has been adjusted to $8.40 from $9.35 as analysts revise their models in response to lower Street price targets and updated expectations for growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on Sight Sciences reflects a mix of renewed interest and caution, with several experts revisiting targets and ratings as they update models for the eyecare and broader medical technology space.Aggiornamento narrativa • Jul 15
SGHT: Medtech Sector Support And Dry Eye Expansion Will Drive Measured Repricing
Analysts have adjusted their stance on Sight Sciences by moving the price target to $6.00 from $5.15, citing updated medtech sector models and a preference for higher-quality stocks during what they describe as a skittish trading backdrop. Analyst Commentary on Sight Sciences Recent commentary on Sight Sciences reflects a mixed tone.Aggiornamento narrativa • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.
Aggiornamento narrativa • Jun 17
SGHT: Sector Support And Dry Eye Execution Will Drive Future Upside
Analysts have increased their price target on Sight Sciences stock to $5.15 from $4.35, citing refreshed medical technology sector models after Q1 updates and a view that broader fundamentals in the space remain solid. Analyst Commentary on Sight Sciences Recent research commentary on Sight Sciences centers on refreshed models following Q1 updates and a reassessment of where the stock fits within the broader medical technology group.Aggiornamento narrativa • Jun 02
SGHT: Dry Eye Execution And TearCare Adoption Will Support Future Upside
Analysts have maintained Sight Sciences' fair value target at $12.00 while refining underlying assumptions such as discount rate and margin forecasts. Recent Street research highlights sector models being refreshed and mixed segment trends as key drivers of the updated $5.15 Citi price target and other revised targets across the stock.Aggiornamento narrativa • May 10
SGHT: Weaker Glaucoma Trends Will Limit Rerating Despite Solid Dry Eye Momentum
Analysts have trimmed their price targets for Sight Sciences, with one key target moving from $6.50 to $5 and another from $12 to $11. These revisions reflect updated views on a mix of steady sector fundamentals, solid Dry Eye performance, and softer Surgical Glaucoma trends.Aggiornamento narrativa • Apr 23
SGHT: Dry Eye Franchise And TearCare Adoption Will Drive Future Upside
The blended analyst price target for Sight Sciences has moved modestly lower to $11 from $12, as analysts balance pressure in Surgical Glaucoma against steady TearCare adoption, sector wide target resets, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research updates show a wide range of views on Sight Sciences, with price targets clustered between the mid single digits and low double digits and ratings spanning Neutral to Buy.Aggiornamento narrativa • Apr 08
SGHT: TearCare And Dry Eye Adoption Will Support Future Upside Potential
Narrative Update on Sight Sciences Analysts have adjusted price targets for Sight Sciences into a range of $5 to $11, reflecting updated views on the balance between softer Surgical Glaucoma trends and stronger TearCare and Dry Eye performance. Overall sector fundamentals are described as healthy.Aggiornamento narrativa • Mar 25
SGHT: Dry Eye Momentum Will Support Stronger Outlook Than Surgical Glaucoma
Analysts have trimmed their average price target on Sight Sciences by $1.00, reflecting updated assumptions around growth, margins and sector risk after recent research highlighted mixed trends between TearCare strength and softer Surgical Glaucoma performance. Analyst Commentary Street research on Sight Sciences has converged around a more cautious but still constructive stance, with price targets adjusted to reflect mixed trends between TearCare strength and softer Surgical Glaucoma performance.Aggiornamento narrativa • Mar 11
SGHT: TearCare Momentum Will Support Rerating Despite Surgical Glaucoma Concerns
The updated analyst price target for Sight Sciences moves to $6.50, reflecting a blended view where some analysts trimmed targets, others raised them toward $8 to $11, and recent feedback on TearCare and mixed segment trends shaped modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Sight Sciences gives you a mixed picture, with some analysts more constructive on TearCare adoption and others turning more cautious on execution and growth in the surgical glaucoma segment.Aggiornamento narrativa • Feb 24
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have maintained their $12.00 price target on Sight Sciences, noting that minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions largely offset one another. What's in the News Sight Sciences issued new earnings guidance for the fourth quarter of 2025, with total revenue expected between $20.3 million and $20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Key Developments).Aggiornamento narrativa • Feb 09
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have kept their price target for Sight Sciences steady at US$12.00, citing updated assumptions that include slightly higher discount and P/E expectations, along with adjusted revenue growth and profit margin forecasts. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue projected between US$20.3 million and US$20.4 million.Aggiornamento narrativa • Jan 26
SGHT: Fair Outlook Balances Guidance Revision With Leadership And Margin Assumptions
Analysts have lifted their price target for Sight Sciences from US$3.60 to US$6.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple as key drivers of the change. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue expected between US$20.3 million and US$20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Corporate Guidance).Articolo di analisi • Jan 21
Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge Could Signal Some Risk
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has softened a substantial 26% over the previous 30 days, handing...Aggiornamento narrativa • Jan 11
SGHT: Final Medicare Coverage Will Support Dry Eye Upside Potential
Analysts have lifted their price target on Sight Sciences from $7.85 to $9.35, citing recent Medicare coverage decisions for the TearCare dry eye disease treatment system as a key support for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the finalized Medicare coverage policies for TearCare as a key support for the higher price targets, since clearer reimbursement can make revenue visibility easier to model.Seeking Alpha • Dec 31
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Summary Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances. SGHT faces significant liquidity risks, and I believe the company should look to raise cash in 2026, particularly in light of the recent share price surge. I see fair value near $9.50/share, but further upside depends on sales execution and additional coverage wins. Read the full article on Seeking AlphaAggiornamento narrativa • Dec 26
SGHT: Medicare Coverage Expansion Will Drive Stronger Outlook For Dry Eye Therapy
Analysts have raised their price target on Sight Sciences from $5 to $7 per share, citing recently finalized Medicare coverage policies for the TearCare dry eye treatment system as a key potential driver of outperformance. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in Sight Sciences' ability to monetize new Medicare coverage for its TearCare dry eye treatment system.Aggiornamento narrativa • Dec 11
SGHT: Final Medicare Coverage Will Shape Dry Eye Outlook And Execution Risks
Analysts have modestly raised their price target on Sight Sciences from approximately $6.08 to about $7.85 per share, citing improved fair value estimates and expectations that finalized Medicare coverage for the TearCare dry eye treatment system could drive future outperformance. Analyst Commentary With the recent coverage decisions for TearCare by key Medicare administrative contractors, Street research has become more constructive on Sight Sciences' medium term outlook, though some execution risks remain in focus.Aggiornamento narrativa • Nov 27
SGHT: Broader Medicare Coverage Will Increase Risks For Execution Going Forward
Analysts have raised their price target for Sight Sciences from $5.00 to $7.00 per share. They cite broader Medicare coverage for its Dry Eye Disease treatment system as a key factor supporting the positive outlook.Articolo di analisi • Nov 13
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aggiornamento narrativa • Nov 08
SGHT: Higher Medicare Access Will Increase Competitive Execution Risks Ahead
Analysts have raised their price target for Sight Sciences from approximately $4.42 to $5.08, citing expanded Medicare coverage and stronger growth expectations across key financial metrics. Analyst Commentary Bullish Takeaways Bullish analysts highlighted the substantial increase in the price target following newly finalized Medicare coverage for the TearCare system.Articolo di analisi • Oct 18
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has done very well over the last month, posting an excellent gain...Articolo di analisi • Aug 09
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
NasdaqGS:SGHT 1 Year Share Price vs Fair Value Explore Sight Sciences's Fair Values from the Community and select yours...Aggiornamento narrativa • Aug 08
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27. What's in the News Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs.Articolo di analisi • May 14
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
Sight Sciences, Inc. ( NASDAQ:SGHT ) shareholders would be excited to see that the share price has had a great month...
Nuova narrativa • Apr 04
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.Articolo di analisi • Mar 30
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Sight Sciences, Inc.'s ( NASDAQ:SGHT ) price-to-sales (or "P/S") ratio of 1.6x might make it look like a buy right now...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 109 | -27 | N/A | N/A | 4 |
| 12/31/2027 | 101 | -29 | N/A | N/A | 7 |
| 12/31/2026 | 90 | -33 | N/A | N/A | 7 |
| 6/30/2026 | 83 | -30 | -23 | -23 | N/A |
| 3/31/2026 | 80 | -37 | -25 | -25 | N/A |
| 12/31/2025 | 77 | -38 | -30 | -30 | N/A |
| 9/30/2025 | 76 | -46 | -32 | -31 | N/A |
| 6/30/2025 | 76 | -49 | -23 | -22 | N/A |
| 3/31/2025 | 78 | -49 | -24 | -24 | N/A |
| 12/31/2024 | 80 | -52 | -23 | -22 | N/A |
| 9/30/2024 | 80 | -50 | -26 | -25 | N/A |
| 6/30/2024 | 79 | -52 | -36 | -36 | N/A |
| 3/31/2024 | 81 | -55 | -40 | -40 | N/A |
| 12/31/2023 | 81 | -56 | -48 | -47 | N/A |
| 9/30/2023 | 83 | -62 | -57 | -56 | N/A |
| 6/30/2023 | 82 | -71 | -67 | -67 | N/A |
| 3/31/2023 | 75 | -80 | -72 | -71 | N/A |
| 12/31/2022 | 71 | -86 | -77 | -76 | N/A |
| 9/30/2022 | 65 | -85 | -72 | -71 | N/A |
| 6/30/2022 | 60 | -80 | -69 | -68 | N/A |
| 3/31/2022 | 55 | -74 | -63 | -62 | N/A |
| 12/31/2021 | 49 | -63 | -53 | -53 | N/A |
| 9/30/2021 | 43 | -56 | -51 | -50 | N/A |
| 6/30/2021 | 39 | -47 | -43 | -42 | N/A |
| 3/31/2021 | 30 | -38 | -36 | -35 | N/A |
| 12/31/2020 | 28 | -35 | -33 | -32 | N/A |
| 12/31/2019 | 23 | -26 | N/A | -25 | N/A |
| 12/31/2018 | 8 | -14 | N/A | -14 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che SGHT rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che SGHT rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che SGHT rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di SGHT ( 11% all'anno) crescerà più lentamente rispetto al mercato US ( 13% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di SGHT ( 11% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che SGHT non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/18 21:16 |
| Prezzo dell'azione a fine giornata | 2026/08/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sight Sciences, Inc. è coperta da 10 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |